001     284361
005     20260130151745.0
024 7 _ |a 10.1007/s00702-025-03096-7
|2 doi
024 7 _ |a pmid:41484430
|2 pmid
024 7 _ |a 0375-9245
|2 ISSN
024 7 _ |a 0022-3026
|2 ISSN
024 7 _ |a 0300-9564
|2 ISSN
024 7 _ |a 1435-1463
|2 ISSN
037 _ _ |a DZNE-2026-00129
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fanciulli, Alessandra
|0 0000-0002-2854-4179
|b 0
245 _ _ |a How to treat cardiovascular autonomic failure in Parkinson's disease.
260 _ _ |a Wien [u.a.]
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769782587_8942
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cardiovascular autonomic failure is a frequent non-motor feature of Parkinson's disease (PD) that affects up to one third of individuals from the premotor to the advanced stages of the disease, with major diagnostic, therapeutic and prognostic implications. It may manifest with orthostatic, post-prandial or exercise-induced hypotension, as well as hypertensive episodes in the supine position during wakefulness or nocturnal sleep. Hypotensive episodes may remain asymptomatic or manifest with symptoms of end-organ hypoperfusion in the upright position, after meals or during exertion that may include lightheadedness, blurred vision, cognitive slowness, shuffling gait, back pain, fatigue or, in severe cases, syncope. Supine and nocturnal hypertension are likewise often asymptomatic, yet may cause nocturnal polyuria, and disrupt sleep through frequent nocturnal toilet visits. Bedside screening for cardiovascular autonomic failure relies on targeted history taking, eventually supported by validated questionnaires, and supine to standing heart rate and blood pressure measurements. A more detailed assessment is obtained with cardiovascular autonomic function tests under continuous, non-invasive, hemodynamic monitoring, complemented by 24-hours ambulatory blood pressure monitoring and home blood pressure diaries. Hypotensive episodes are managed by addressing potential triggers, such as infections, anemia, dehydration and polypharmacy, followed by a stepwise implementation of behavioral, non-pharmacological and pharmacological strategies. Individuals with orthostatic hypotension should be constantly monitored for concomitant supine and nocturnal hypertension, especially if treatment with pressor agents has been recently started. Hypertensive episodes are likewise treated in a stepwise fashion with preventive, non-pharmacological and pharmacological measures, prioritizing hypotension control during daytime and mitigating hypertension overnight.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Nocturnal hypertension
|2 Other
650 _ 7 |a Orthostatic hypotension
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Post-prandial hypotension
|2 Other
650 _ 7 |a Supine hypertension
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
650 _ 2 |a Autonomic Nervous System Diseases: etiology
|2 MeSH
650 _ 2 |a Autonomic Nervous System Diseases: therapy
|2 MeSH
650 _ 2 |a Autonomic Nervous System Diseases: diagnosis
|2 MeSH
650 _ 2 |a Cardiovascular Diseases: therapy
|2 MeSH
650 _ 2 |a Cardiovascular Diseases: etiology
|2 MeSH
650 _ 2 |a Cardiovascular Diseases: diagnosis
|2 MeSH
700 1 _ |a Leys, Fabian
|0 0000-0003-1714-5305
|b 1
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 2
700 1 _ |a Jost, Wolfgang H
|0 0000-0002-8574-3297
|b 3
773 _ _ |a 10.1007/s00702-025-03096-7
|g Vol. 133, no. 2, p. 215 - 228
|0 PERI:(DE-600)1481655-6
|n 2
|p 215 - 228
|t Journal of neural transmission
|v 133
|y 2026
|x 0375-9245
856 4 _ |u https://pub.dzne.de/record/284361/files/DZNE-2026-00129.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/284361/files/DZNE-2026-00129.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURAL TRANSM : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21